Saudi Arabia Diabetes Drug Market Research Report: Forecast (2025-2030)

Market Definition

Diabetic drugs aid individuals afflicted with the disease to maintain their blood glucose levels. They cannot heal the patient but they reduce the likelihood of complications.

Market Insights & Analysis: Saudi Arabia Diabetes Drug Market (2025-2030):

The Saudi Arabia Diabetes Drug Market size was valued at around USD 2 billion in 2024 and is projected to reach USD 3.4 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 9% during the forecast period (2025-30). The rate of diabetes is intensively increasing in the region which is creating the demand for the drugs. Also, the increasing spending on the healthcare system with government programs and support is further driving the demand for Diabetes drugs in Saudi Arabia. The government has also been focusing on providing insurance coverage for diseases and the incorporation of new technologies for cutting-edge treatment options for diabetes.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

The youth in the region are at a higher risk for developing the disease currently leading to the increase in healthcare costs, adverse quality of life coupled with shorter life expectancy. The Saudi Arabian region is suffering from diabetes intensively as in about 10 people more than 1 is suffering from the disease and the ubiquity of the disease will almost double by 2045. Also, the report by the IDF indicates that around 1.86 million citizens in Saudi Arabia have diabetes but still not recognized yet. Currently, 4.27 million Saudi Arabian people have diabetes. This number is expected to grow to 5.6 million by 2030 and can reach 7.5 million by 2045. The ubiquity of diabetes is increasing in Saudi Arabia with unhealthy lifestyles and an increasingly obese population, ultimately creating a heavy demand for the Saudi Arabia Diabetes Drug Market.

By 2030, a 10% reduction is planned by Saudi Arabia in the ubiquity of diabetes. Moreover, they have provided multiple investments for diabetes drugs to promote market growth. For instance; Saudia Arabia provided 25-35% of their healthcare budget for various diseases like obesity and diabetes. It also included cardiovascular diseases caused due to adverse diabetes in the region. Other government initiatives include high taxation on sugary drinks and a focus on preventive diabetes care coupled with fitness programs. They imposed a 50% tax on various beverages containing high sugar, in the past few years. In addition to this, a 100% tax was also imposed on energy drinks. Combating diabetes by the government, along with the higher purchasing power of the people in the country, may help the market for diabetes drugs during the forecast period.

Saudi Arabia Diabetes Drug Market Driver:

High Prevalence of Diabetes Propelling Market Growth – Due to genetic predispositions and unhealthy lifestyle choices, Saudi Arabia has one of the highest prevalence rates in the world. By 2026, around 24% of the total adult population of Saudi Arabia is expected to have Diabetes which was just around 17.7% in 2021. This rising prevalence is leading the nation to become the 2nd highest in the Middle East and 7th highest globally in diabetes occupancy. An unhealthy lifestyle has resulted in the prevalence of obesity-related problems in Saudi Arabia that majorly pose a threat to several chronic diseases like Type-2 diabetes. An approximate 35.4% of the adult population of Saudi Arabia suffers from obesity. This creates an immense nationwide demand for Diabetes Drugs for the treatment and prevention of diabetes, thereby significantly contributing to the market growth.

Another reason is the country has some of the highest per capita consumption of sugar-filled drinks which worsens the diabetes epidemic. High prevalence rates of the disease result from this sort of sedentary behavior allied with diets full of fat and sugar which fuels the growth of the Saudi Arabia Diabetes Drug Market.

Saudi Arabia Diabetes Drug Market Opportunity:

Rising Focus on Advanced Therapies – Saudi Arabia is seeing a rise in the use of several cutting-edge therapies including SGLT-2 inhibitors and basal insulin analogs coupled with GLP-1 receptors which presents several growth prospects. To lower obesity they aid in weight management, which is one of the main causes of diabetes in Saudi Arabia. Due to the high incidence of diabetes-related heart problems in Saudi Arabia SGLT-2 inhibitor drugs like Jardiance empagliflozin are gaining popularity because of their capacity to reduce blood sugar levels and the risk of cardiovascular complications. The shift is supported by Saudi Vision 2030 which places a strong emphasis on modernizing healthcare and guaranteeing access to it. The government can help pharmaceutical companies meet demand and enhance public health outcomes by increasing awareness among patients and adding coverage under insurance.

Saudi Arabia Diabetes Drug Market Challenge:

High Treatment Costs to Hinder Market Growth – High treatment costs are a huge challenge in the Saudi Arabia diabetes Drug Market. Advanced cures like GLP-1 receptor agonists can be very costly ultimately putting an economic burden on both patients and the healthcare system. Regardless of the availability of biosimilars, which provide an extra inexpensive opportunity, many patients still face challenges due to the high prices of brand-name medications. For instance; advanced insulins like Lantus and Novorapid remain costly, especially for the ones without comprehensive insurance coverage. The government’s healthcare initiatives aim to cope with these costs by introducing measures to reduce treatment expenses and increase access to crucial medications. However, affordability remains a vital barrier for many patients.

Saudi Arabia Diabetes Drug Market Trend:

Increasing Penetration of Biosimilar Insulins – Biosimilar insulins are becoming popular in Saudi Arabia due to their cost-effectiveness and equivalence to branded insulin analogs. The alternative options ensure the cost-effective provision of vital diabetes medications without compromising on accessibility. Biosimilar insulin is often priced lower than its branded counterpart and may even be up to 10–30% cheaper. This has been triggered by the Saudi Arabian government's health care reforms, increased number of diabetic patients, and measures to enhance prudent use of health care. Although biosimilar insulins still lag behind branded insulins in terms of market share, the footprint is rapidly increasing, and an approximate 10% market share in the insulin segment in Saudi Arabia has been estimated. The adoption of biosimilar insulins also demonstrates Saudi Arabia's desire to balance cost management with high-quality diabetes care. This fits within the broader healthcare reforms, where sustainable treatment solutions can be provided to the growing diabetic population in the country.

Saudi Arabia Diabetes Drug Market (2025-2030): Segmentation Analysis

The Saudi Arabia Diabetes Drug Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the national level. Based on the analysis, the market has been further classified as:

Based on Insulins:

• Basal
• Bolous
• Traditional Insulins
• Biosimilar Insulins

Based on the Insulins, Basal leads the Saudi Arabia Diabetes Drugs Market. It holds approximately 43.75% share of the total market. Products such as Lantus, Levemir, and Tresiba fall in this category. They are known to maintain a stable blood glucose level for an extended period. High use of the drugs in clinical settings of Saudi Arabia and their efficacy in controlling Type 1 and Type 2 diabetes are reasons for the growth. Such basal insulin need can further be augmented because a large majority percentage of Saudi Arabia's diabetics have Type 2 diabetes that often progresses to the point where long-acting insulin becomes a requirement in treatment. Also, diabetes education and care funded by the Saudi government that promotes early diagnosis and treatment compliance align with using basal insulin.

Based on the Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Clinics and Diabetes Centers

Based on the distribution channel, Hospital Pharmacies lead the Saudi Arabia Diabetes Drugs Market. It holds approx. 40% share of the total global market. This leadership emanates from their position as a central care center for the management of diabetes, especially for severe complications or the use of advanced drugs like insulin and injectables. Specialty care is provided through endocrinologists and diabetes specialists who dispense advanced therapies, mostly available only in these pharmacies. Public hospitals, under the Ministry of Health, distribute essential drugs for diabetes at discounted prices or for free, which makes them more accessible in Saudi Arabia. Hospitals also play an important role in chronic disease management programs, where medication is accompanied by patient education and lifestyle interventions. All these factors contribute to major dependence on hospital pharmacies and make them the most preferable distribution channel.

Saudi Arabia Diabetes Drug Market (2025-30): Regional Projections

Geographically, the Saudi Arabia Diabetes Drug Market expands across:

• Northern
• Central
• Southern
• Eastern
• Western

Based on region the central region leads the Saudi Arabia Diabetes Drugs Market. It holds approx. 37.5% market share. The higher urban population and population density in the region are related to higher rates of diabetes due to sedentary lifestyles and eating habits. In addition, central Saudi Arabia provides the best access to modern medical facilities and specialists. In this region, more aggressive diabetes management and awareness campaigns can be seen. Furthermore, urban centers like Riyadh have more per capita income, making it easier for citizens to get medication and other treatments including expensive ones like insulin analogs and combination therapies.

 Saudi Arabia Diabetes Drug Industry Recent Development:

• October 2024: Novo Nordisk A/S announced an agreement with Lifera. Through Lifera’s subsidiary, SaudiBio, the two companies have agreed to localize insulin production in Saudi Arabia.
• August 2024: Boehringer Ingelheim and Alpha Pharma collaborated to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia. Alpha Pharma, aims to combat type 2 diabetes in the Kingdom and is fully aligned with the Kingdom’s Vision 2030 pillars.

Gain a Competitive Edge with Our Saudi Arabia Diabetes Drug Market Report

1. Saudi Arabia Diabetes Drug Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps business organizations to gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing business organizations to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. The Saudi Arabia Diabetes Drug Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, business organizations can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.